We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.
We have leveraged our expertise and capabilities both to commercialize three vaccines, including the world’s first and only chikungunya vaccine, and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease and Zika.
With operations in Austria, Canada, France, Sweden, the United Kingdom, and the U.S., we are committed to making a positive impact on global public health.
Together, we are a global Company which is open to people of all backgrounds. Our diverse and inclusive workforce makes Valneva a great place to work.
Our Finance team are now recruiting for an Accounts Payable Supervisor
Our Accounts Payable Supervisor will be responsible for leading the day-to-day Accounts Payable (AP) function across multiple international legal entities, ensuring timely and accurate processing of supplier invoices and vendor payments. As well as being hands-on in terms of invoice processing, the role provides operational leadership to a team of two AP professionals, drives process improvements, ensures compliance with internal controls and local regulatory requirements, and supports business stakeholders across multiple countries.
The position plays a key role in maintaining strong vendor relationships, managing payment cycles, supporting month-end close activities, and ensuring a high standard of service delivery within a multinational environment.
Requirements
Experience
Benefits

Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.
We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first and only chikungunya vaccine, as well as certain third-party vaccines.
Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.
Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with approximately 700 employees.